Aortic lesions requiring fenestration or branch aortic isolation
Conditions
Interventions
Aortic lesions requiring fenestration or branch aortic isolation:Peripheral covered stents or bare stents (including ball-expandable stents and self-expanding stents)
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-80 years, male or female; 2. Aortic dissection or aortic aneurysm was diagnosed by computed tomography angiography (CTA) or digital subtracted angiography (DSA); 3. The research subjects meet the surgical indications for endovascular treatment, and are reconfirmed by intraoperative angiography and treated with f/b-EVAR with branch artery reconstruction; 4. The research subjects agree to cooperate with postoperative thoracoabdominal aorta CTA examination and follow-up; 5. Good compliance, the patient himself or his legal representative signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with aortic disease diagnosed with connective tissue diseases such as Marfan syndrome; 2. Patients diagnosed with aortic disease with drug addiction, syphilis or mental disorders; 3. Patients with ruptured aortic aneurysm requiring emergency surgery; 4. Preoperative evaluation of patients with irreversible damage to the blood supply organs of the involved branches; 5. Patients with severe liver disease accompanied by decompensated cirrhosis, jaundice, ascites or bleeding; 6. The NYHA classification of cardiac function belongs to class III or IV; or patients with heart failure; 7. Patients with cerebral infarction, cerebral hemorrhage, myocardial infarction, unstable angina pectoris within the past 3 months; 8. Patients with malignant tumors whose expected survival time is less than 2 years; 9. Those who are receiving immunosuppressants, hemodialysis, tumor chemotherapy and radiation therapy; 10. Patients who are known to be allergic to aspirin, heparin, Plavix, and contrast agents; 11. Have participated in clinical trials of drugs or other medical devices that interfere with this clinical trial within the past 3 months; 12. Those who cannot comply with the research protocol; 13. The investigator believes that the subject has potential risks or any other factors that interfere with the subject.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary patency rate of target vessel bridging stent; | — |
Countries
China
Contacts
Public ContactDai Xiangchen
Tianjin Medical University General Hospital
Outcome results
None listed